A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
Latest Information Update: 29 Jun 2025
At a glance
- Drugs Upadacitinib (Primary)
- Indications Hidradenitis suppurativa
- Focus Registrational; Therapeutic Use
- Acronyms Step-Up HS
- Sponsors AbbVie
Most Recent Events
- 11 Jun 2025 Ptorocol has been amended(Addition of new primary endpoint i.e Number of Participants with Adverse Events (AEs)).
- 04 Jun 2025 Planned End Date changed from 1 Aug 2027 to 1 Mar 2028.
- 04 Jun 2025 Planned primary completion date changed from 1 Feb 2026 to 1 Mar 2028.